Peer-reviewed veterinary case report
FIV-infected cats treated with two interferon omega protocols studied
By Leal, Rodolfo O et al.·Published in Research in veterinary science·2015·University of Lisbon (ULisboa), France·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Evaluation of viremia, proviral load and cytokine profile in naturally feline immunodeficiency virus infected cats treated with two different protocols of recombinant feline interferon omega.
- Species:
- cat
Plain-English summary
A group of cats with feline immunodeficiency virus (FIV) were treated with two different protocols of interferon omega to see how it affected their health. Some cats received the treatment through injections, while others took it orally. The results showed that while the treatment reduced certain inflammatory markers in the blood, it did not significantly change the overall viral load or improve other immune responses. However, the treatment did help lower levels of a specific inflammatory marker (IL-6) in both groups. Overall, interferon omega may help reduce inflammation in FIV-infected cats, but more research is needed to see its full effects.
People also search for: cat FIV treatment · feline immunodeficiency virus symptoms · interferon omega for cats
Abstract
This study assesses viremia, provirus and blood cytokine profile in naturally FIV-infected cats treated with two distinct protocols of interferon omega (rFeIFN-ω). Samples from FIV-cats previously submitted to two single-arm studies were used: 7/18 received the licensed/subcutaneous protocol (SC) while 11/18 were treated orally (PO). Viremia, provirus and blood mRNA expression of interleukin (IL)-1, IL-4, IL-6, IL-10, IL-12p40, Interferon-γ and Tumor Necrosis Factor-α were monitored by Real-Time qPCR. Concurrent plasma levels of IL-6, IL-12p40 and IL-4 were assessed by ELISA. IL-6 plasma levels decreased in the SC group (p = 0.031). IL-6 mRNA expression (p = 0.037) decreased in the PO group, albeit not sufficiently to change concurrent plasma levels. Neither viremia nor other measured cytokines changed with therapy. Proviral load increased in the SC group (p = 0.031), which can be justified by a clinically irrelevant increase of lymphocyte count. Independently of the protocol, rFeIFN-ω seems to act on innate immunity by reducing pro-inflammatory stimulus.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/25747956/